Related Experiment Video

Updated: May 15, 2026

Ex Vivo Corneal Organ Culture Model for Wound Healing Studies
06:46

Ex Vivo Corneal Organ Culture Model for Wound Healing Studies

Published on: February 15, 2019

Targeting focal adhesion kinase in fibrotic diseases

David Lagares1, Mohit Kapoor

  • 1Department of Medicine, Pulmonary and Critical Care Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|January 19, 2013
PubMed

Insights

Focal adhesion kinase (FAK) is a key regulator in fibrotic diseases like pulmonary fibrosis. Targeting FAK offers a promising therapeutic strategy for treating these chronic conditions.

Area of Science:

  • Fibrosis research
  • Molecular biology
  • Drug discovery

Background:

  • Fibrotic diseases, including idiopathic pulmonary fibrosis and scleroderma, are chronic fibroproliferative disorders with no effective treatments.
  • These conditions result from dysregulated tissue repair, leading to excessive extracellular matrix deposition and impaired organ function.
  • The precise mechanisms driving fibrosis remain poorly understood.

Purpose of the Study:

  • To review the emerging role of focal adhesion kinase (FAK) in fibrotic signaling.
  • To explore the potential of FAK as a therapeutic target for antifibrotic therapy.

Main Methods:

  • Literature review of recent findings on FAK's role in fibrosis.
  • Analysis of FAK's function as a regulator of fibrotic signaling pathways.

Main Results:

  • Recent findings implicate focal adhesion kinase (FAK) in the development of fibrotic disorders.
  • FAK appears to be a critical regulator of fibrotic signaling.

Conclusions:

  • FAK is a key player in the pathophysiology of fibrotic diseases.
  • Targeting FAK presents a promising therapeutic avenue for antifibrotic treatments.

More Related Videos

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

Related Concept Videos

Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...